A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer

Front Immunol. 2022 Nov 14:13:1027449. doi: 10.3389/fimmu.2022.1027449. eCollection 2022.

Abstract

Background: Bladder cancer (BLCA) is one of the deadliest diseases, with over 550,000 new cases and 170,000 deaths globally every year. Cuproptosis is a copper-triggered programmed cell death and is associated with the prognosis and immune response of various cancers. Long non-coding RNA (lncRNA) could serve as a prognostic biomarker and is involved in the progression of BLCA.

Methods: The gene expression profile of cuproptosis-related lncRNAs was analyzed by using data from The Cancer Genome Atlas. Cox regression analysis and least absolute shrinkage and selection operator analysis were performed to construct a cuproptosis-related lncRNA prognostic signature. The predictive performance of this signature was verified by ROC curves and a nomogram. We also explored the difference in immune-related activity, tumor mutation burden (TMB), tumor immune dysfunction and exclusion (TIDE), and drug sensitivity between the high- and low-risk groups.

Results: We successfully constructed a cuproptosis-related lncRNA prognostic signature for BLCA including eight lncRNAs (RNF139-AS1, LINC00996, NR2F2-AS1, AL590428.1, SEC24B-AS1, AC006566.1, UBE2Q1-AS1, and AL021978.1). Multivariate Cox analysis suggested that age, clinical stage, and risk score were the independent risk factors for predicting prognosis of BLCA. Further analysis revealed that this signature not only had higher diagnostic efficiency compared to other clinical features but also had a good performance in predicting the 1-year, 3-year, and 5-year overall survival rate in BLCA. Notably, BLCA patients with a low risk score seemed to be associated with an inflamed tumor immune microenvironment and had a higher TMB level than those with a high risk score. In addition, patients with a high risk score had a higher TIDE score and a higher half maximal inhibitory concentration value of many therapeutic drugs than those with a low risk score.

Conclusion: We identified a novel cuproptosis-related lncRNA signature that could predict the prognosis and immune landscape of BLCA.

Keywords: BLCA; cuproptosis; immune; lncRNA; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis*
  • Copper
  • Humans
  • Nomograms
  • Prognosis
  • RNA, Long Noncoding* / genetics
  • Receptors, Cell Surface
  • Risk Factors
  • Tumor Microenvironment / genetics
  • Ubiquitin-Conjugating Enzymes
  • Urinary Bladder Neoplasms* / genetics

Substances

  • Receptors, Cell Surface
  • RNA, Long Noncoding
  • RNF139 protein, human
  • UBE2Q1 protein, human
  • Ubiquitin-Conjugating Enzymes
  • Copper